The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors

被引:36
作者
Jacobs, M. N. [1 ]
Janssens, W. [2 ]
Bernauer, U. [3 ]
Brandon, E. [4 ]
Coecke, S.
Combes, R.
Edwards, P.
Freidig, A. [5 ]
Freyberger, A.
Kolanczyk, R. [6 ]
Mc Ardle, C. [7 ]
Mekenyan, O.
Schmieder, P. [6 ]
Schrader, T.
Takeyoshi, M.
van der Burg, B.
机构
[1] Commiss European Communities, Joint Res Ctr, Inst Hlth & Consumer Protect, Vitro Toxicol Unit,ECVAM, I-21027 Ispra, Italy
[2] Sci Inst Publ Hlth, Atlanta, GA 30314 USA
[3] BfR Fed Inst Risk Assessment, Berlin, Germany
[4] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands
[5] TNO, Nutr & Food Res, Bilthoven, Netherlands
[6] US EPA, Kansas City, KS USA
[7] Univ Bristol, Bristol BS8 1TH, Avon, England
关键词
Endocrine disruption; endocrine active substances; metabolism; cytochrome P450; estrogenicity; androgenicity;
D O I
10.2174/138920008786049294
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
引用
收藏
页码:796 / 826
页数:31
相关论文
共 332 条
[1]   Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques [J].
Afzelius, L ;
Raubacher, F ;
Karlén, A ;
Jorgensen, FS ;
Andersson, TB ;
Masimirembwa, CM ;
Zamora, I .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (11) :1218-1229
[2]   Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis [J].
Afzelius, L ;
Zamora, I ;
Ridderström, M ;
Andersson, TB ;
Karlén, A ;
Masimirembwa, CM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :909-919
[3]   A metabolite of methoxychlor, 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane, reduces testosterone biosynthesis in rat leydig cells through suppression of steady-state messenger ribonucleic acid levels of the cholesterol side-chain cleavage enzyme [J].
Akingbemi, BT ;
Ge, RS ;
Klinefelter, GR ;
Gunsalus, GL ;
Hardy, MP .
BIOLOGY OF REPRODUCTION, 2000, 62 (03) :571-578
[4]   Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line [J].
Altuntas, TG ;
Zager, RA ;
Kharasch, ED .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 193 (01) :55-65
[5]  
ANDERS MW, 1986, BIOL REACT INTERMED, V3, P443
[6]   Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals [J].
Andersen, HR ;
Andersson, AM ;
Arnold, SF ;
Autrup, H ;
Barfoed, M ;
Beresford, NA ;
Bjerregaard, P ;
Christiansen, LB ;
Gissel, B ;
Hummel, R ;
Jorgensen, EB ;
Korsgaard, B ;
Le Guevel, R ;
Leffers, H ;
McLachlan, J ;
Moller, A ;
Nielsen, JB ;
Olea, N ;
Oles-Karasko, A ;
Pakdel, F ;
Pedersen, KL ;
Perez, P ;
Skakkeboek, NE ;
Sonnenschein, C ;
Soto, AM ;
Sumpter, JP ;
Thorpe, SM ;
Grandjean, P .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1999, 107 :89-108
[7]  
ANDERSEN HR, 1999, ENV HLTH PERSPECT, V107, pS1
[8]  
[Anonymous], OECD GUID TEST CHEM
[9]   Validation of in vitro and in vivo methods for assessing endocrine disrupting chemicals [J].
Ashby, J .
TOXICOLOGIC PATHOLOGY, 2000, 28 (03) :432-437
[10]  
*ASS LIF SCI, 1981, HLTH EFF NITR NITR 1, pCH4